pharmaphorum July 16, 2024
After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.
The San Diego, California-based biotech filed its intention to go public a couple of weeks ago and has now set out its terms, hoping to raise up to $135 million by offering 8.7 million shares at a price range of $14 to $16. It had initially set a target of $100 million from the IPO.
Artiva is one of a group of companies that are hoping to mimic with NK cells what has been done with T cells, and specifically CAR-Ts for cancer which account for the majority of approved cell therapies at the moment.
Dr Fred...
Today's Sponsors
Today's Sponsor